Contraception After Pregnancy, endorsed by the Royal Colleges: GPs; Obstetricians and Gynaecologists; Nurses and Midwives, aims to guide healthcare professionals to inform and support the women in their care to make planned choices about future pregnancies and improve maternal and child outcomes through optimum spacing between children.
Filter documents Clear search
It is anticipated that following the current period of Covid-19 lockdown, there will be an ongoing requirement for social distancing. The Faculty of Sexual and Reproductive Healthcare (FSRH) makes recommendations relating to contraceptive services at times when lockdown restrictions are eased.
FSRH CEU Guidance: Recommended Actions after incorrect Use of Combined Hormonal Contraception (e.g. late or missed pills, ring and patch) (March 2020, amended July 2021)
This document provides guidance on incorrect use of: combined oral contraceptive pills, the combined vaginal ring, and the combined transdermal patch. This guidance was developed with an international team of SRH experts. The panel used the limited relevant published evidence relating to risk of pregnancy associated with incorrect use of the combined pill, patch and ring to inform a set of rules that are overcautious, but are considered to be simple enough to make them usable in practice. The guidance was peer reviewed and went out to public consultation prior to final publication. The guidance is intended for use by health professionals working in SRH, general practice and obstetric and gynaecology settings, and can also be used by women using CHC. Download the document here.
This guidance provides evidence-based recommendations and good practice points for health professionals on the use of intrauterine contraception (IUC) currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK. This guideline was updated in September 2019.
FSRH Clinical Guideline: Contraception for Women Aged over 40 Years (August 2017, amended September 2019)
This update of the 2010 Contraception for Women Aged Over 40 Years guideline has been developed by the FSRH and brings together evidence and expert opinion on contraception for women aged over 40 years. The guideline was developed with a team of experts in the relevant fields and has been extensively peer reviewed in accordance with methodology used for developing FSRH Clinical Guidelines. The guidance is intended for use by health professionals working in SRH, general practice and obstetric and gynaecology settings. This guideline was amended in September 2019.
Change of UKMEC category for use of progestogen-only injectable contraception and intrauterine contraception by women at high risk of HIV infection from UKMEC2 to UKMEC1 (September 2019).
FSRH Guideline-related Resources: Quick Reference Summary of Clinical Guidance on Overweight, Obesity and Contraception (July 2019)
This summary has been written as a quick reference guide to help busy clinicians give clear, safe advice on contraception for women who are overweight or with obesity. Please refer to the full Overweight, Obesity and Contraception guideline for further information and evidence for this advice. Members should log into the website and view this guidance under 'My Resouces' on the website.
This guidance provides evidence-based recommendations and good practice points for health professionals providing contraceptive services to young people in the UK. This guidance is most relevant to young people under 18 years of age but may also apply to young people up to the age of 25 years.
This guidance provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only pills currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK.
This new document aims to summarise the available evidence on contraceptive choices for women who are overweight and women with obesity (i.e. with body mass index 25 kg/m2 or higher). This guideline evaluates the interrelationship between contraception and weight and considerations such as bariatric surgery and weight loss medication.